Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups

Haifaa Abdulhaq, William Townsend, Matthew Ku, Gareth P. Gregory, Jeremy Abramson, Huiqiang Huang, Huilai Zhang, Dok Hyun Yoon, Won-Seog Kim, Herve Ghesquieres, Mark Hertzberg, Qing-Yuan Zhang, Murali Kesavan, Estefania Mulvihill, Martine Joanna Kallemeijn, Richard Ta, Voleak Choeurng, Linda Lundberg, Christopher Fox

Blood (2025) 146 (Supplement 1): 3743.

https://doi.org/10.1182/blood-2025-3743

Published: 2025

Journal Articles

Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO

Blood (2025) 146 (Supplement 1): 5519.

https://doi.org/10.1182/blood-2025-5519

Published: 2025

Journal Articles

Evaluating the efficacy of montelukast in reducing the incidence and severity of monoclonal antibodies-associated infusion reactions (Phase II Study)

Omar Mahmood, Christopher Leung, Palak Tohan, Richard Ward, Joseph Mosholder, Haifaa Abdulhaq, Sani Bukari

Blood (2025) 146 (Supplement 1): 6196.

https://doi.org/10.1182/blood-2025-6196

Published: 2025

Journal Articles

A Phase II trial of obinutuzumab, ibrutinib and venetoclax in patients with previously untreated follicular lymphoma; A University of California hematologic malignancies consortium study

Aneeqa Zafar, Naseem Esteghamat, Haifaa Abdulhaq, Shuai Chen, Siyao Li, Paul Kaesberg, Rasmus Hoeg, Aaron Tsumura, Benjamin Heyman, Patricia A. Young, Sani Bukari, Carolyn Mulroney, Herbert Eradat, Aaron Rosenberg, Joseph Tuscano

Blood (2025) 146 (Supplement 1): 5378.

https://doi.org/10.1182/blood-2025-5378

Published: 2025

Journal Articles

Cost effectiveness of in-house HIT screening testing in community based hospital

Jankikeerthika Dharmarpandi, Nam Huynh, Omar Mahmood, Christopher Leung, Haifaa Abdulhaq, Sani Bukari

Blood (2025) 146 (Supplement 1): 4380.

https://doi.org/10.1182/blood-2025-4380

Published: 2025

Journal Articles

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts)

Blood (2025) 146 (Supplement 1): 3775.

https://doi.org/10.1182/blood-2025-3775

Published: 2025

Journal Articles

CRS-RS.5p predictive model informs risk stratification and cytokine release syndrome management following glofitamab treatment in patients with relapsed or refractory diffuse large B-cell lymphoma

Haifaa Abdulhaq, Linda Lundberg, Anton Belousov, James Relf, Rachel Linacre, Gareth P. Gregory

Blood (2025) 146 (Supplement 1): 2559.

https://doi.org/10.1182/blood-2025-2559

Published: 2025

Journal Articles

Somatic mutations and clinical outcomes in primary central nervous system lymphoma among hispanic and non-hispanic patients: A study from the University of California hematologic malignancies consortium (UCHMC)

Haifaa Abdulhaq, Omar Mahmood, nathan Futoran, Sani Bukari, Calvin Chen, Joseph Tuscano, Aaron Tsumura, Tamer Othman, Elizabeth Brem, Chenchen Niu, Benjamin Heyman, Michelle Don, Azra Borogovac, Matthew Wieduwilt, Maher Albitar

Blood (2025) 146 (Supplement 1): 1755.

https://doi.org/10.1182/blood-2025-1755

Published: 2025

Journal Articles

Pembrolizumab + GVD with ctdna-guided consolidation for relapsed/refractory classic Hodgkin lymphoma: A multicenter phase 2 Study of the University of California hematologic malignancies consortium

Michael Randall, Wendy Swetzig Dhiman, Chiung-Yu Huang, Charalambos Andreadis, Weiyun Ai, Carrie Ho, Mwanasha Merrill, Madhav Seshadri, Haifaa Abdulhaq, Joseph Tuscano, Nicole Foley, Patricia A. Young, William Pearse, Stephanie Meek, David Kurtz, Michael Spinner

Blood (2025) 146 (Supplement 1): 3630.

https://doi.org/10.1182/blood-2025-3630

Published: 2025

Journal Articles

Interim analysis of a Phase I/II study of tafasitamab with lenalidomide in patients with relapsed central nervous system lymphoma

Michael Randall, Andreas Rauschecker, Lingjing Chen, Ming Lu, Jordan Roselli, Rosalynn Ruiz, Haifaa Abdulhaq, James Rubenstein

Blood (2025) 146 (Supplement 1): 1969.

https://doi.org/10.1182/blood-2025-1969

Published: 2025

Journal Articles

Efficacy and safety of loncastuximab tesirine and rituximab (Lonca-R) followed by dose-adjusted rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine and prednisone (DA-R-EPOCH) in previously untreated high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary results from a University of California Malignancy Consortium (UCHMC) Phase II trial, UCDCC#303.

Jacqueline Hsieh-Wong, Naseem Esteghamat, Rasmus Hoeg, Mehrdad Abedi, Sheila Firoozan, Aaron Rosenberg, Ashley Trane, Aneeqa Zafar, Shuai Chen, Siyao Li, Matthew Wieduwilt, Lloyd Damon, Benjamin Heyman, Haifaa Abdulhaq, Elizabeth Brem, Deepa Jeyakumar, Gary Schiller, Joseph Tuscano

Blood (2025) 146 (Supplement 1): 1966.

https://doi.org/10.1182/blood-2025-1966

Published: 2025

Journal Articles

Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study

Gareth P. Gregory, Jeremy S. Abramson, Hui-Qiang Huang, Qing-Yuan Zhang, Matthew Ku, Dok Hyun Yoon, Christopher P. Fox, Haifaa Abdulhaq, William Townsend, Joan Ashby, Alana Harris, Victor Orellana-Noia, Stephen Simko, Martine Kallemeijn, Richard Ta, James Relf, Huang Huang, Linda Lundberg, Huilai Zhang

Blood (2024) 144 (Supplement 1): 5132.

https://doi.org/10.1182/blood-2024-198424

Published: 2024

Journal Articles

Optimizing Acute Sickle Cell Care at Community Health Partners Medical Center

Jeffrey T Means, Nicole Palmer, Jeffrey Uller, Daniel Park, Andrew Hwang, Brian Chinnock, Marsha Treadwell, Patrick Macmillan, Haifaa Abdulhaq, Wesley Viau, Nivedana Ravi, Sani Bukari

Blood (2023) 142 (Supplement 1): 7234.

https://doi.org/10.1182/blood-2023-187948

Published: 2023

Journal Articles

Trends in Diffuse Large B-Cell Lymphoma Mortality in the United States: A Comprehensive Review from 2000 to 2020

Abdul Rahman Al Armashi, Anas Al Zubaidi, Omar Mahmood, Marisa Thierheimer, Akram Alkrekshi, Haifaa Abdulhaq

Blood (2023) 142 (Supplement 1): 1765.

https://doi.org/10.1182/blood-2023-180270

Published: 2023

Journal Articles

Trial in Progress: A Phase I/II Study of Tafasitamab Plus Lenalidomide in Patients with Relapsed CNS Lymphoma

Michael P Randall, Andreas Rauschecker, Liam Gima-Lange, Jenai Wilmoth, Lingjing Chen, Ming Lu, Huimin Geng, Haifaa Abdulhaq, James L. Rubenstein

Blood (2023) 142 (Supplement 1): 3104.

https://doi.org/10.1182/blood-2023-190698

Published: 2023

Journal Articles

Realmind: A Prospective and Retrospective Study to Characterize Real-World Use of Tafasitamab Plus Lenalidomide in US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, with a Focus on Patients from Minority Groups

Elizabeth A. Brem, John M. Burke, Mirko Vukcevic, Pia Kloepfer, Kimberly Saverno, Haifaa Abdulhaq, Andrew M Evens, Pierluigi Porcu, Mazyar Shadman, Christopher R. Flowers

Blood (2023) 142 (Supplement 1): 6251.

https://doi.org/10.1182/blood-2023-188482

Published: 2023

Journal Articles

Disparities in Genetic Profiles, Risk Stratification and Outcomes in Adults with Acute Myeloid Leukemia Comparing Patients of Hispanic and Non-Hispanic Ethnicity in Central California

Omar Mahmood, Tanjot Saini, Daniel Park, Sundeep Bekal, Inderpreet Bal, Simran Saini, Tabark Altai, Yousef Fayed, Yueqi Yan, Haifaa Abdulhaq

Blood (2023) 142 (Supplement 1): 7423.

https://doi.org/10.1182/blood-2023-184600

Published: 2023

Journal Articles

A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma

Tamer Othman, Aaron S Rosenberg, John Timmerman, Benjamin Heyman, Haifaa Abdulhaq, Joseph M Tuscano

Blood (2022) 140 (Supplement 1): 11954–11955.

https://doi.org/10.1182/blood-2022-164905

Published: 2022

Journal Articles

Impact of Timing of Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis

Tamer Othman, Michelle A. Quan, Shiliang Zhang, Daria Gaut, Patricia A. Young, Haifaa Abdulhaq, Kevin Shieh, Jack Reid, Elizabeth A. Brem, Benjamin Heyman, Joseph Tuscano

Blood (2022) 140 (Supplement 1): 4851–4852.

https://doi.org/10.1182/blood-2022-163552

Published: 2022

Journal Articles

Disparities in Somatic Mutations and Outcomes in Primary Central Nervous System Lymphoma Comparing Patients of Hispanic and Non-Hispanic Ethnicity

Haifaa Abdulhaq, Omar Mahmood, Calvin Kuan Jung Chen, Azra Borogovac, Matthew Wieduwilt, Anand Annan, Yueqi Yan, Maher Albitar

Blood (2022) 140 (Supplement 1): 3553–3554.

https://doi.org/10.1182/blood-2022-164902

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups

Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO

Evaluating the efficacy of montelukast in reducing the incidence and severity of monoclonal antibodies-associated infusion reactions (Phase II Study)

A Phase II trial of obinutuzumab, ibrutinib and venetoclax in patients with previously untreated follicular lymphoma; A University of California hematologic malignancies consortium study

Cost effectiveness of in-house HIT screening testing in community based hospital

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts)

CRS-RS.5p predictive model informs risk stratification and cytokine release syndrome management following glofitamab treatment in patients with relapsed or refractory diffuse large B-cell lymphoma

Somatic mutations and clinical outcomes in primary central nervous system lymphoma among hispanic and non-hispanic patients: A study from the University of California hematologic malignancies consortium (UCHMC)

Pembrolizumab + GVD with ctdna-guided consolidation for relapsed/refractory classic Hodgkin lymphoma: A multicenter phase 2 Study of the University of California hematologic malignancies consortium

Interim analysis of a Phase I/II study of tafasitamab with lenalidomide in patients with relapsed central nervous system lymphoma

Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study

Optimizing Acute Sickle Cell Care at Community Health Partners Medical Center

Trends in Diffuse Large B-Cell Lymphoma Mortality in the United States: A Comprehensive Review from 2000 to 2020

Trial in Progress: A Phase I/II Study of Tafasitamab Plus Lenalidomide in Patients with Relapsed CNS Lymphoma

Realmind: A Prospective and Retrospective Study to Characterize Real-World Use of Tafasitamab Plus Lenalidomide in US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, with a Focus on Patients from Minority Groups

Disparities in Genetic Profiles, Risk Stratification and Outcomes in Adults with Acute Myeloid Leukemia Comparing Patients of Hispanic and Non-Hispanic Ethnicity in Central California

A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma

Impact of Timing of Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis

Disparities in Somatic Mutations and Outcomes in Primary Central Nervous System Lymphoma Comparing Patients of Hispanic and Non-Hispanic Ethnicity

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only